Father’s Day is just around the corner, but many dads won’t be around to celebrate. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the U.S.
Voiding the bladder is one of the most basic human functions, so mundane that we pay it little mind most of the time.
Access Pharmaceuticals (OTC: ACCP.OB, “Access”) develops and commercializes products for the treatment and supportive care of cancer patients.
Vivostat is a Danish company that uses the patient’s blood to create a personalized surgical glue (fibrin sealant) that can be used for surgical procedures and the treatment of diabetic ulcers.
The Aliso Viejo, Calif.-based company achieved several major milestones in 2009.
The significant differences between Echo Therapeutics’ Symphony system and the competition is the needle-free transdermal biosensor, clinical trials in the hospital setting and biosensor life.
Access Pharma (OTC: ACCP.OB) provided an update today on the status of its cobalamin-based oral drug delivery product development programs.
NuVue Therapeutics is commercializing a site-specific regimen of cancer therapy for soft tissue tumors.
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
The drug candidate IL13-PE has the potential to be the first effective therapy for idiopathic pulmonary fibrosis (IPF), which kills an estimated 40,000 people in the United States each year.
Copyright © 2025 | WordPress Theme by MH Themes